Aumolertinib vs Gefitinib as First-Line Therapy for Locally Advanced or Metastatic NSCLC With EGFR Exon 19 Deletion or L858R Mutations
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations
J. Clin. Oncol 2022 May 17;[EPub Ahead of Print], S Lu, X Dong, H Jian, J Chen, G Chen, Y Sun, Y Ji, Z Wang, J Shi, J Lu, S Chen, D Lv, G Zhang, C Liu, J Li, X Yu, Z Lin, Z Yu, Z Wang, J Cui, X Xu, J Fang, J Feng, Z Xu, R Ma, J Hu, N Yang, X Zhou, X Wu, C Hu, Z Zhang, Y Lu, Y Hu, L Jiang, Q Wang, R Guo, J Zhou, B Li, C Hu, W Tong, H Zhang, L Ma, Y Chen, Z Jie, Y Yao, L Zhang, W Jie, W Li, J Xiong, X Ye, J Duan, H Yang, M Sun, C Sun, H Wei, C Li, SM Ali, VA Miller, Q WuFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.